Does the FDA now consider HRT safe

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

According to FDA.gov, modern hormone therapy may be appropriate for most healthy women when used at the lowest effective dose for the shortest duration needed to control symptoms. The FDA does not issue a blanket statement calling HRT "safe" or "unsafe" — rather, it identifies specific risks and specific benefits that must be weighed for each individual by a qualified prescriber.

Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

How the FDA views HRT today

According to FDA.gov, the agency evaluates hormone therapy based on the type of hormone, route of administration, and individual patient health history rather than a single categorical judgment. Key points from FDA guidance include:

• HRT may be effective for hot flashes, night sweats, vaginal dryness, and prevention of bone loss.
• Most healthy women under 60 or within about 10 years of menopause may have a lower overall risk profile when using HRT, according to FDA-approved prescribing information.
• Risks depend on the type of hormone (estrogen alone vs. estrogen with progesterone), the route (pill vs. patch), and an individual's personal health history.
• Women with a uterus need progesterone with estrogen to protect the uterine lining, per FDA-approved labeling.
• Transdermal estrogen (patch, gel, spray) may carry a lower clot risk than oral estrogen, according to the FDA-approved prescribing information for transdermal hormone products.

Which risks the FDA still highlights

According to FDA Drug Safety Communications, certain women face elevated risk. FDA boxed warnings do not indicate the therapy is inappropriate for all women — they direct clinicians to exercise careful judgment in prescribing.

• Breast cancer: According to the WHI, slightly increased risk has been observed with long-term estrogen-progestin use; estrogen alone showed little to no increase for many women in that study.
• Blood clots and stroke: According to FDA Drug Safety Communications, these risks are more strongly associated with oral estrogen; transdermal forms may carry lower risk.
• Cardiovascular risk: According to the FDA-approved prescribing information for hormone therapies, risk depends substantially on age; initiating HRT after age 60 may carry higher cardiovascular risk than initiating near menopause.

What this means for a woman deciding about HRT

• According to NAMS, women who are healthy, under 60, and close to menopause onset may find that benefits outweigh risks — but this determination should be made with a qualified prescriber.
• If you have certain conditions (breast cancer history, active clotting disorder, recent stroke or heart attack), non-hormonal options may be preferred, per FDA guidance.
• Individualized assessment is key: dose, hormone type, delivery method, and health history all influence the benefit-risk profile and should be evaluated by a qualified prescriber.

According to FDA.gov, hormone therapy is a well-studied option that may be appropriate for many women when prescribed thoughtfully and monitored through routine care. All treatment decisions should be made in consultation with a qualified prescriber.